Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress Sep 5, 2017
Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors Sep 1, 2017
Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans Aug 14, 2017
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117 Jul 10, 2017
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting Jun 4, 2017
Rexahn Pharmaceuticals to Present RX-3117 Clinical Data at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting May 8, 2017
